Table 1.
Patient characteristics.
| RA | AS | Total | |
|---|---|---|---|
| n | 36 | 17 | 53 |
| Female:male | 31:5 | 3:14 | 34:19 |
| Age (mean ± SD)(range), years | 55.9 ± 9.8 (35–83) | 43.6 ± 12.4 (24–72) | 52.0 ± 12.1 (24–83) |
| Disease duration (mean ± SD) (range), years | 9.1 ± 8.3 (1–44) | 7.2 ± 7.0 (1–26) | 8.5 ± 7.9 (1–44) |
| Menopausal status (number of women) | 25 | 1 | 26 |
| Menopause duration (in menopausal women), years | 11.0 ± 7.6 | 23.0 | 12.0 ± 7.8 |
| Menopausal hormone replacement (number of women) | 7 | 1 | 8 |
| BMI (mean ± SD), kg/m2 | 29.3 ± 3.6 | 31.1 ± 3.8 | 29.9 ± 3.7 |
| Obesity (BMI > 30 kg/m2) | 17 | 11 | 28 |
| Smoking (current) | 7 | 7 | 14 |
| Positive CV history | 8 | 1 | 9 |
| Diabetes mellitus history | 3 | 1 | 4 |
| Hypertension history | 17 | 4 | 21 |
| Fragility fracture history (events/patients) | 14/10 | 8/7 | 22/17 |
| Corticosteroid use at baseline (mean ± SD), years | 3.8 ± 5.9 | 0.6 ± 0.9 | 2.8 ± 5.1 |
| RF positivity, n (%) | 26 (72) | – | – |
| ACPA positivity, n (%) | 21 (58) | – | – |
| DAS28 (baseline) (mean ± SD) | 5.00 ± 0.86 | – | – |
| BASDAI (baseline) (mean ± SD) | – | 5.79 ± 1.19 | – |
| Treatment (ETN, CZP) | 20 ETN, 16 CZP | 17 ETN | 37 ETN, 16 CZP |
ACPA, anti-citrullinated protein antibody, AS, ankylosing spondylitis, BASDAI Bath ankylosing spondylitis disease activity score, BMI body mass index, CV cardiovascular, CZP certolizumab pegol, DAS28 28-joint disease activity score, ETN etanercept, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation.